Dodge & Cox Purchases 2,769 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Dodge & Cox increased its stake in Regeneron Pharmaceuticals by 0.1% during the first quarter, owning a total of 2,324,085 shares valued at approximately $1.47 billion.
• Several institutional investors significantly boosted their holdings in Regeneron in the fourth quarter, with Brighton Jones LLC increasing its stake by 261.8%.
• Research firms set new price targets for Regeneron, with Morgan Stanley raising its target to $761 and BMO Capital Markets to $640, signaling strong investor confidence in the stock's performance.

Dodge & Cox grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,324,085 shares of the biopharmaceutical company's stock after acquiring an additional 2,769 shares during the quarter. Dodge & Cox owned about 2.13% of Regeneron Pharmaceuticals worth $1,474,004,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Brighton Jones LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after buying an additional 686 shares during the last quarter. American Assets Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $427,000. MML Investors Services LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 41.7% in the fourth quarter. MML Investors Services LLC now owns 7,533 shares of the biopharmaceutical company's stock worth $5,366,000 after buying an additional 2,218 shares during the last quarter. Integrated Wealth Concepts LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 55.5% in the fourth quarter. Integrated Wealth Concepts LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $828,000 after buying an additional 415 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 3,839 shares of the biopharmaceutical company's stock worth $2,735,000 after buying an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on REGN. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Trading Down 1.5%

Regeneron Pharmaceuticals stock opened at $589.48 on Friday. The stock has a market cap of $62.48 billion, a P/E ratio of 14.86, a PEG ratio of 1.99 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm's 50 day moving average price is $550.48 and its 200-day moving average price is $592.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $11.56 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.